Novartis announces positive data from phase III study of intrathecal onasemnogene abeparvovec in broad patient population with SMA: Basel Friday, March 21, 2025, 11:00 Hrs [IST] N ...

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...

The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.

Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...

Primary care clinicians are often the most accessible to patients and play a crucial role in the early detection and ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Inc. , today announced a definitive merger agreement under which Bristol Myers Squibb ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash ...

The safety profile of crizanlizumab was in line with previous findings, with pyrexia, headache, and nausea being commonly reported adverse events. Grade 3 or higher adverse events were less ...

Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...